Day: 29 3 月, 2025

- HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in hospital coverage. Compared with the 2023 year, sales volume increased by approximately 740%.- Sales revenue increased by 234% compared with the 2023 year, with cash reserves exceeding RMB 1 billion to fully support future R&D and commercialization activities.- A Phase I clinical study of our second-generation GKA, a once daily oral therapy, successfully completed in the United States. Our dorzagliatin-metformin fixed-dose combination formulation progressed smoothly and our product pipeline continued to advance and expand.- The Mendelian Randomization studies of human genetic data provided scientific evidence to support the exploration of glucokinase activation in diabetic complications and new clinical indications.- Manufacturing capacity of dorzagliatin continued to expand to meet growing market demand.- The establishment of Hua Medicine’s pharmaceutical sales and marketing team resulted in significant sales growth in the first two months of 2025, opening a new model of innovative drug commercialization.SHANGHAI, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the “Reporting Period”), along with the Company’s business progress in 2024 and future business outlook. Hua Medicine has made significant strides in the commercialization of its core product, the glucokinase activator (GKA) dorzagliatin (trade name: HuaTangNing, as well as in R&D innovation and manufacturing capacity optimization, laying a solid foundation for the Company’s long-term sustainable development.Dr. Li Chen, Founder and the Chief Executive Officer of Hua Medicine, stated: “In 2024, HuaTangNing’s market performance was very encouraging. Its inclusion in the NRDL greatly enhanced the accessibility and affordability of this innovative drug, enabling more diabetes patients to benefit. In 2025, Hua Medicine established a pharmaceutical sales and marketing team, and HuaTangNing demonstrated strong growth momentum at the start of the year. With further market expansion and increasing patient awareness, we are confident in HuaTangNing’s market growth.”“Looking ahead, the Company will continue to explore HuaTangNing’s potential in personalized diabetes treatment and diabetes complications globally. By integrating big data and artificial intelligence technologies, we aim to expand our disease areas into immune homeostasis and neural homeostasis. We are confident with the close collaboration of Hua Medicine and its partners across the pharmaceutical R&D, production, and distribution chain, we can enable more patients to access and benefit from Chinese medicines, accelerating progress in realizing our vision ‘China leading pharmaceutical innovation to advance human health.’”Summary of Clinical Research and Operational Progress- Significant Revenue Growth, Strong Market Performance of HuaTangNing, and Positive Patient Feedback- 2024 marked the first full year for which our HuaTangNing was reimbursed under the National Reimbursement Drug List (“NRDL”) in China. Sales revenue increased by 234% to RMB255.9 million for the fiscal year 2024 compared with the same period in 2023. During the fiscal year 2024, HuaTangNing was sold in approximately 2,700 hospitals across China. As of December 31, 2024, Hua Medicine maintained a strong balance sheet with a cash balance of RMB1,139.8 million to support its full-scale commercialization, business development and R&D functions.- Since the launch of HuaTangNing in the fourth quarter of 2022, our pharmacovigilance team has been diligently monitoring the safety of dorzagliatin in the China market, and was recently recognized by the National Adverse Drug Reaction Monitoring Center as a national example for the pharmaceutical industry. As of December 31, 2024, Hua Medicine had monitored approximately 150,000 patients who have been prescribed HuaTangNing, and dorzagliatin has been observed to be safe and well tolerated by patients.- Effective January 1, 2025, Hua Medicine assumed full responsibility for the commercialization of HuaTangNing in China from its former sales and marketing partner, Bayer Healthcare Company Limited (“Bayer”). We recruited Mr. Lu Yu, a seasoned pharmaceutical sales executive with over 20 years of diabetes commercialization experience in China, to lead our sales and marketing efforts.- For the two months ended February 28, 2025, Hua Medicine sold approximately 592,000 packs of HuaTangNing, representing approximately RMB73.2 million in net sales. During the same period in 2024, approximately 202,000 packs of HuaTangNing were sold, representing approximately RMB24.5 million in net sales, The difference represents a significant increase in sales over a period during which the price per pack remained the same. This demonstrates a smooth transition of HuaTangNing’s commercialization in China from Bayer to Hua Medicine, with reinvigorated growth momentum.- Upon the termination of the Exclusive Promotion Service Agreement, the unamortized contact liabilities amounting to RMB1,243,499,000 were released to profit or loss, and will be recognized as a gain in 2025 by the Group. Both parties have confirmed in a signed letter that there are no outstanding matters arising from such termination, nor does either party owe the other party any obligation or liabilities from such separation.- Steady Progress in R&D Innovation, Continuously Enriching Product Pipeline- Hua Medicine made significant headway in preparing the future expansion of our glucokinase-targeted, glucose homeostasis-centered therapy into the international markets, specifically the United States. We successfully completed and announced the results of its single-ascending dose (“SAD”) study in the United States of our second generation GKA (HM-002-1005), in which we validated the feasibility of dorzagliatin as a once daily oral therapy for Type 2 diabetes (“T2D”) patients. We are currently developing the clinical dosage form for advancement of HM-002-1005 in a clinical proof-of-mechanism study.- Hua Medicine also made significant progress in developing fixed-dose combination formulations. The Company has been advancing its dorzagliatin-metformin fixed-dose combination product candidate into commercial dosage development, with process validation expected to be completed in 2025.- Based on human genetic data collected from studies of patients administered with dorzagliatin, the Mendelian Randomization methodology has been applied to predict the beneficial effects of dorzagliatin on related and significant diabetes complications, such as reduction in heart failure, coronary artery disease, memory loss and dyslipidemia. In addition, a separate Mendelian Randomization study provided genetic evidence supporting the causal effects of glucokinase activation on lowering the risk of frailty. These findings suggest that glucokinase activators may aid in the management of frailty and sarcopaenia in people with diabetes. We will continue our research and development efforts to explore new indications.- Through our SENSITIZE 3 clinical study in Hong Kong, Hua Medicine is advancing the potential of dorzagliatin in prediabetes, early treatment and prevention of Type 2 diabetes. In contrast with the approved 75mg dosage form of HuaTangNing, the Company is testing new 25mg and 50mg dosage formulations to explore these potential new indications. The Company is also supporting an investigator-sponsored trial in testing dorzagliatin’s efficacy in treating MODY-2 patients who suffered from genetic mutations that de-activated glucokinase. Early studies in humans by renowned diabetes experts Dr. Juliana Chan and Dr. Linong Ji have indicated the benefit of dorzagliatin in MODY-2 patients by improving their β-cell functions and glycemic control.- Hua Medicine is also advancing the combination of dorzagliatin with GLP-1RA, DPP-IV inhibitors and SGLT-2 inhibitor through combined effects in collecting real-world evidence and proof-of-concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indication into other diseases in metabolic disorders, such as obesity and MASH. - Hua Medicine will continue our engagement in diabetes prevention, opportunities in longevity and prevention of memory loss and eventually find a new way to increase healthy life span and longevity in humans.- Continued Expansion of Manufacturing Capacity, Plans to Launch Dorzagliatin in New Markets- Hua Medicine continues to invest in expanding its manufacturing capacity to meet anticipated market needs in 2026 and 2027.- Hua Medicine is also finalizing and preparing to submit registration applications for dorzagliatin to launch commercialization in the Macau and Hong Kong markets. We plan to submit both applications in 2025.- Hua Medicine continues to strengthen its intellectual property protection globally. As of December 31, 2024, the Company owned more than 200 granted patents covering its proprietary technology worldwide.Business outlook- There is a great opportunity for dorzagliatin and our 2nd generation GKA in China and the global oral anti-diabetes market. - We will strengthen our own commercialization efforts through hub and spoke development with focus on building up a strong internal sales and medical marketing organization to drive business growth in 2025. This will allow us to rebuild our strong connections directly to the medical community and better promote HuaTangNing in China and surrounding areas.- We continue to invest into digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.- We are working on the registration of dorzagliatin in HK and Macau region and engage partnerships in Southeastern Asia and Belt and Road nations. In addition, business development work on our 2nd generation GKA in regions with high incidences of obesity will be continued based on the initial success of the SAD study in the United States.Financial SummaryFor the year ended December 31, 2024:- Bank balances and cash position was approximately RMB1,139.8 million.- Total revenue was approximately RMB255.9 million, an increase of approximately 234% compared to the full year of 2023; approximately 2,105,000 packs of HuaTangNing were sold, an increase of approximately 740% compared to the full year of 2023.- Total other income was approximately RMB116.8 million, including approximately RMB95.7 million from the amortization of Bayer milestone income.- Total expenditures for the year was approximately RMB493.6 million, of which R&D expenses accounted for approximately RMB215.1 million.- Loss before tax was approximately RMB250.1 million, which was mainly attributable to the increase of selling expense and research and development expense.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more information Hua MedicineWebsite:www.huamedicine.comInvestorsEmail:ir@huamedicine.comMediaEmail:pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2024 (the “Year” or “FY2024”).Financial Highlights- Contracts-in-hand remained at a high level of HK$11,052.7 million- Revenue rose to HK$6,450.1 million, up 5.2% year-on-year- Adjusted profit attributable to owners of the company recorded HK$206.0 million 1 with a growth of 10.2% 2 year-on-year, excluding a one-off expense and provision- Total dividend for the year amounted to HK4.38 cents per shareChairman Dr Mak Kin Wah said, “Capturing opportunities from shifting market priorities towards intelligent and digital solutions, data centres, environmental engineering and climate solutions, hospitals, infrastructure, and housing, we maintained a high level of contracts-in-hand across the Group’s diverse scope of business, providing a strong underlying foundation for the business over the next two years and beyond; this was notwithstanding the challenges around the world and in Hong Kong during the year.ATAL Tower, our new headquarters, is a significant investment that demonstrates our confidence in the future and our commitment to Hong Kong. We will continue to leverage our expertise and strong financial position to take up additional opportunities in the Hong Kong market, and explore further business development in overseas markets. Our investment in research and development, and innovation will enhance our core strengths and competitiveness. We will tirelessly live up to our motto of ‘We Commit. We Perform. We Deliver.’, ultimately driving our sustainable growth, optimising value for shareholders and other stakeholders, and contributing to the wider community.”Business Review: Building Services- This segment is the largest revenue contributor, with revenue up 5.3% to HK$3,933 million.- The recurring maintenance revenue increased by 40.2% to HK$422 million.- Leadership in the innovative construction technology of Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) received a major boost during the year, not only with the award of significant contract for a Grade A office building in Causeway Bay with the highest level of MiMEP application at 85% for a commercial building, but also with the development of our own systematic MiMEP methodologies and solutions.- The “MiMEP Design and Manufacturing Centre” and “MiMEP High Productivity Research Centre” in Zhuhai, as well as other MiMEP manufacturing facilities in Hong Kong, were established to integrate our capabilities in the Greater Bay Area with cutting-edge technology from Hong Kong.Environmental Engineering- The order intake significantly increased by 107.4% to HK$1,514 million, with contracts won for environmental infrastructure needed to enhance climate resilience, environmental protection, sustainability of water supply and waste treatment, and support for public housing and utilities.- The segment actively extended its expert services around the world, including Teresa in the Philippines, Dubai and other parts of the world.Information, Communications and Building Technologies (“ICBT”)- The order intake increased 22.5% to HK$757 million, with contracts-in-hand up 13.8% to HK$959 million.- The segment actively collaborated with leading manufacturers worldwide and in Mainland China to expand its technology reach and deliver cutting-edge solutions in diverse sectors.Lifts and Escalators- There was a significant growth in order intake and revenue, up 48.5% to HK$548 million and up 39.9% to HK$529 million respectively.- The two recently acquired lift companies in the United Kingdom (“UK”) contributed to revenue growth and made progress in the UK business.- The associate in the United States turned from a loss to a profit in FY2024 and made progress in expanding its business into additional cities in the South.For further details of the 2024 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.Remark:1. Profit attributable to the owners of the Company was HK$135.3 million, including a one-off expense of approximately HK$23.1 million before tax for relocation to the new consolidated headquarters to realise enhanced efficiency and synergy across business units, and a provision for expected credit loss of HK$88.0 million before tax to reflect risks with the recoverability of certain receivables and contract assets held by the Group in relation to certain construction companies.2. When compared with the adjusted profit attributable to owners of the company of HK$186.9 million in FY2023, which excludes a one-off dilution gain before tax upon completion of a private placement by an associate in Mainland China, a gain on disposal of interest before tax in an associate, and a provision before tax in respect of certain contracts in the healthcare sector.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2025 ACN Newswire via SeaPRwire.com.

- 华堂宁(R)被纳入国家医保药品目录后的首个完整年度，销量较2023年增加740%- 销售收入较2023年增加234%，现金储备超10亿，充分支持未来研发和商业化活动- 第二代每天一次口服GKA在美国的I期临床研究成功完成，多格列艾汀-二甲双胍固定复方制剂顺利推进，产品管线布局逐渐丰富- 人类基因孟德尔随机化研究提供科学证据，支持葡萄糖激酶激活在糖尿病并发症和新适应症的开发- 多格列艾汀生产能力继续扩大，满足不断增长的市场需求- 建立华领医药药品市场销售团队，2025年前两月销售额显著增长，开启创新药商业化新模式上海, 2025年3月28日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552）宣布公司及其附属公司截至2024年12月31日止，经审核的全年业绩（"报告期"），以及公司2024年业务进展和未来业务展望。华领医药在核心产品葡萄糖激酶激活剂（GKA）多格列艾汀片（商品名：华堂宁(R)）的商业化，以及公司研发创新、产能优化等方面均取得了重要进展，为公司的长期可持续发展奠定了坚实基础。华领医药创始人、首席执行官陈力博士表示："2024年，华堂宁(R)的市场表现令人振奋，进入国家医保目录极大提高了产品的可及性和可负担性，使得更多糖尿病患者能够受益于这一创新药物。2025年，华领医药建立了药品市场销售团队，华堂宁(R)在年初展现出了良好的增长势头，随着市场的进一步拓展和患者认知度的提升，我们对华堂宁(R)的市场增长充满信心。未来公司将在全球范围内继续探索华堂宁(R)在糖尿病个性化治疗以及糖尿病并发症等领域的用药潜力，并且结合大数据和人工智能技术,在免疫稳态和神经稳态方面，拓展我们的疾病治疗领域。相信在华领医药及其药品研发、生产、经销商运营等产业链伙伴的密切合作下，我们能让更多患者用上中国药、受益于中国药，加快推进'中华引领医药创新，造福人类健康进展'的公司愿景。"临床研究和公司运营进展摘要- 收入显著增长，华堂宁(R)市场表现强劲，用药反馈积极- 2024年是公司核心产品华堂宁(R)进入国家医保药品目录后的首个完整销售年度。公司销售收入达到人民币2.559亿元，较2023年增加234%，华堂宁(R)的销售覆盖了约2700家医院。截至 2024 年12月31日，华领医药现金结余达人民币11.398亿元，以支持公司的全面商业化、业务发展和研发活动。- 自2022年第四季度华堂宁(R)上市以来，华领医药药物警戒团队始终高度关注对多格列艾汀药物安全性的监测。近期，公司被国家药品不良反应监测中心评为受表扬企业。截至2024年12月31日，华领医药已经监测了约15万名开具华堂宁(R)处方的患者，结果显示安全性良好，患者耐受性佳。- 自2025年1月1日起，华领医药从原市场营销合作伙伴拜耳医药保健有限公司（"拜耳"）手中全面接管华堂宁(R)在中国的商业化工作。公司已聘请资深销售人士陆宇先生负责销售和市场工作，他在中国的糖尿病药物商业化方面具有超过20年的经验。- 截至2025年2月28日止，华领医药在2025年前两月共售出约59.2万盒华堂宁(R)，净销售额约为人民币7320万元；相比2024年同期的20.2万盒和2450万元，净销售净额增长显著，在每盒价格维持不变的情况下，销售额增长199%。这也证明华领医药已经顺利接管华堂宁(R)在中国的商业化工作，且焕发出新的发展动力。- 与拜耳终止独家推广服务协议后，未摊销的合同负债付款约12.435亿元人民币将，将在2025年确认为公司收益。双方已在所签立的函件中确认，概无任何因有关终止而引致的未决事项，双方亦无因该分立而对彼此负有任何义务或责任。- 研发创新稳步推进，持续丰富产品管线布局- 华领医药计划将以葡萄糖激酶为靶点、以血糖稳态为核心的疗法拓展至国际市场，特别是美国市场。2024年，公司在推进该项工作中取得了重大进展。公司成功完成并公布了第二代GKA（HM-002-1005）在美国的单剂量递增（SAD）研究结果，验证了每日一次口服疗法用于肥胖2型糖尿病患者的可行性。公司目前正在开发临床剂型，以推进HM-002-1005的临床机制验证研究。- 华领医药在固定复方制剂的开发上也取得了重要进展，公司正在推进多格列艾汀-二甲双胍固定复方制剂候选产品的商业化剂型开发，预计在2025年完成工艺验证。- 根据从接受多格列艾汀治疗的患者研究中收集的人类基因数据，应用孟德尔随机化研究方法，预测多格列艾汀可能对糖尿病相关重大并发症产生获益，如降低心力衰竭、冠状动脉疾病、记忆力减退和血脂异常等的风险。此外，一项独立的孟德尔随机化研究提供了遗传学证据，支持葡萄糖激酶的激活对降低虚弱风险存在因果效应。这些研究结果表明，葡萄糖激酶激活剂可能有助于控制糖尿病患者的体弱和肌肉疏松症。公司将继续开展研发工作，以探索新的临床适应症。- 通过在中国香港进行的 SENSITIZE 3临床研究，华领医药正在推进多格列艾汀在糖尿病前期、2型糖尿病早期治疗和预防方面的潜力。区别于已经获批的75mg华堂宁(R)剂型，公司正在研究25mg和50mg新剂型，以探索上述新的潜在适应症。公司也在支持一项由研究者发起的研究，以探索多格列艾汀对患有葡萄糖激酶失活的基因突变（MODY-2）患者的治疗效果。糖尿病领域知名专家陈重娥（Juliana Chan）教授和纪立农教授的进人研究均表明，多格列艾汀可改善MODY-2患者的β细胞功能和血糖控制。- 华领医药正在通过收集现实世界证据和动物模型的概念验证研究，推进多格列艾汀与GLP-1RA、DPP-4抑制剂及SGLT-2抑制剂的联合用药研究。多格列艾汀与上述药物的协同增效作用有望将其适应症拓展至代谢紊乱相关的其它疾病，如肥胖及代谢性相关的脂肪肝病。- 华领医药将继续糖尿病预防、长寿机会以及记忆力衰退预防方面的研究，以期获得延长人类健康寿命并实现长寿的全新方案。- 产能投资继续扩大，多格列艾汀计划推广新市场- 华领医药继续扩大产能的投资，以满足2026年和2027年的预期市场需求。- 华领医药正在准备多格列艾汀在中国澳门和中国香港市场的商业化的注册申请材料，公司计划在 2025 年提交这两项申请。- 华领医药继续在全球范围内加强知识产权保护。截至2024年12月31日，公司在全球范围内拥有超过 200 项涵盖专有技术的授权专利。业务展望- 在中国及全球口服抗糖尿病药物市场，多格列艾汀和第二代GKA存在巨大市场机遇。- 华领医药将通过枢纽及辐射式发展模式来强化自身的商业化能力，重点打造华领医药内部销售和医学营销团队作为强大的枢纽，以推动2025年的业务增长。公司将建立与医疗界的紧密联系，更有效地在中国及周边地区推广华堂宁(R)。- 华领医药将继续投资数字技术平台，以实现跨职能协同效应，并利用人工智能技术提升品牌机遇。- 华领医药正在推进多格列艾汀在香港和澳门地区的注册工作，并积极寻求与东南亚及"一带一路"沿线国家建立合作关系。此外，基于在美国进行的SAD研究的初步成功，公司将继续在西方肥胖人口密集地区开展第二代GKA的业务拓展工作。财务摘要截至2024年12月31日止，- 公司银行结余及现金约11.398亿元。- 销售收入约为人民币2.559亿元，较2023年全年增加约234%；共销售约210.5万盒华堂宁(R)，较2023年全年增加约740%。- 其他收入约为1.168亿元，其中拜耳里程碑收益摊销约9570万元。- 年度总开支约4.936亿元，其中研发开支约2.151亿元。- 税前亏损约 2.501 亿元人民币，主要原因是销售费用和研发费用的增加。前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港, 2025年3月28日 - (亚太商讯 via SeaPRwire.com) - 领先的机电工程与智慧城市的资讯及通讯科技服务供应商安乐工程集团有限公司（「安乐工程」或「公司」，连同附属公司统称（「集团」））（股份代号：1977），今天宣布截至2024年12月31日止年度（「年内」或「2024财政年度」）的全年业绩。财务摘要- 手头合约总值维持在110.527亿港元高位- 收益上升至64.501亿港元，按年增加5.2%- 扣除一次性开支及拨备，经调整本公司拥有人应占溢利为2.06亿港元1，按年增加10.2%2- 全年合共派息每股4.38港仙主席麦建华博士表示：「尽管年内全球及香港面临挑战，我们凭借多元化的业务范畴，把握转趋于智能及数码解决方案、数据中心、环境工程和气候解决方案、医院、基建和房屋等市场机遇，使手头合约维持高位，为未来两年及未来的业务发展奠定稳固的基础。」「新总部安乐工程大厦的启用，不仅是集团对未来发展的重要投资，亦彰显我们对香港前景信心满满。我们将继续发挥专业知识和财务优势，把握更多香港市场的机会，并拓展海外市场的新业务发展。持续投资于研发和创新将增强我们的核心优势和竞争力。我们将贯切实践『重承诺、慎履行、献成果』的座右铭，推动可持续增长，最终为股东和其他持份者创造最佳价值，贡献社会。」业务回顾：屋宇装备工程- 该业务板块对集团的收益贡献最大，收益上升5.3%，达39.33亿港元。- 经常性维修保养收益增加40.2%至4.22亿港元。- 在创新建筑技术 - 机电装备合成法（「MiMEP」）的业界领导地位于年内获得进一步提升，不仅获得重大合约，为铜锣湾一幢甲级办公大楼应用MiMEP达85%，属商业楼宇的最高水平，更自主研发系统化的MiMEP指引及解决方案。- 在珠海设立「机电装备合成法设计及建造中心」和「机电装备合成法高效生产研发中心」，以及于香港设立相关的MiMEP生产设施，旨在将我们于大湾区的生产力与香港的尖端技术相结合。环境工程- 订单额大幅增长107.4%至15.14亿港元，主要由于赢得的合约涉及加强气候适应力、环境保护、供水及废物处理的可持续性，以及支持公共房屋及公用事业所需的环境基建。- 积极将其优质服务扩展至全球，包括菲律宾特蕾莎(Teresa)、杜拜及全球其他地区。资讯、通讯及屋宇科技（「ICBT」）- 订单额增加22.5%至7.57亿港元，手头合约价值上升13.8%至9.59亿港元。- 积极与全球及中国内地的领先生产商合作，以扩大技术应用范畴，并为不同领域提供先进技术的解决方案。升降机及自动梯- 订单额和收益均获得显著的增长，分别提升48.5%至5.48亿港元和39.9%至5.29亿港元。- 近年收购的两家英国升降机公司对收益增长作出贡献，并推动英国业务取得进展。- 美国联营公司于2024财政年度实现转亏为盈，并将业务进一步扩展至美国南部其他城市。有关2024年度业绩详情，请参阅已呈交香港联合交易所有限公司的公告。注：1.本公司拥有人应占溢利为1.353亿港元，当中包括因搬迁至新综合总部以增强业务部门之间的效率及协同效应而产生一次性税前开支约2,310万港元，以及预期信贷亏损的税前拨备8,800万港元，以反映与若干建筑公司有关的应收款项及合约资产可收回性的风险。2.比较2023财政年度经调整本公司拥有人应占溢利1.869亿港元（已撇除一间中国内地联营公司完成私人配售后一次性税前摊薄收益、出售于联营公司权益的税前收益及就若干医疗保健业务合约的税前拨备）。关于安乐工程集团有限公司安乐工程集团有限公司成立于1977年，为领先的机电工程与智慧城市的资讯及通讯科技服务供应商，总部设于香港，业务遍及澳门、中国内地、美国及英国。本集团为不同行业，包括公共和私营的客户提供跨专业、综合性的机电工程和技术服务，涵盖屋宇装备工程、环境工程、资讯、通讯及屋宇科技（「ICBT」），以及升降机及自动梯等四大业务板块。本集团同时制造及向全球销售Anlev升降机及自动梯，并与美国纽约最大独立升降机及自动梯公司之一Transel Elevator & Electric Inc.（「TEI」）达成伙伴关系。本集团的联营公司南京佳力图机房环境技术股份有限公司（603912.SS）专门制造精密空调设备。 Copyright 2025 亚太商讯 via SeaPRwire.com.

Mahe, Seychelles, 2025年3月28日 - (亚太商讯 via SeaPRwire.com) - 由科技企业家和战略家 Kristof Schöffling 领导的 Move Digital Limited，发布了 2025 年的雄心勃勃蓝图，巩固其在人工智能（AI）、区块链和机器人技术创新领域的全球领导地位。Move Digital 在摩纳哥、泰国、东京、悉尼和香港等地运营，致力于在主流技术采纳之前，将先进科技融入日常生活。基于实绩的 2025 年愿景拥有超过 15 年经验并成功退出多个科技项目的企业家 Kristof Schöffling，凭借识别变革性趋势的能力，建立了他作为一名前瞻性企业家的声誉。在他的领导下，Move Digital 从区块链创新者发展成为一家全球顶尖公司，提供 AI 驱动的消费者应用、为家族办公室提供的高端咨询服务以及前沿的机器人制造。"人工智能不应该仅仅是董事会或实验室中的一个概念。"Schöffling 说。"Move Digital 的使命是将智能解决方案带入日常生活，为所有人群提供便利、自由和效率。"现实世界中的 AIMove Digital 的 AI 部门正在全球推出分布式应用，简化日常事务、提高生产力，并提升不同人群的使用体验。这些解决方案旨在使 AI 不再神秘化，并为企业、家庭和机构展示其实际价值。为家族办公室及全球投资者提供战略咨询服务随着对可信科技顾问需求的急剧增长，Schöffling 将 Move Digital 的业务范围扩展到家族办公室和高净值人士的战略咨询服务。该公司现在与摩纳哥、东京、曼谷和香港等金融中心的传统投资者合作，帮助他们应对 AI 战略、数字化转型及区块链创新。"AI 已经不再是科技公司的游乐场。它是根本性的经济资产。"Schöffling 说。"无论是管理全球投资组合还是运营传统企业，整合 AI 现在是保持竞争力的关键。"机器人技术：Move Digital 的下一个边疆2025 年，Move Digital 将进军机器人领域，并在越南和中国开发生产设施。这些设施将生产由模块化 AI 系统和连接数字基础设施驱动的智能家用机器人。预计全球机器人市场将从 2024 年的 460 亿美元增长至 2032 年的超过 1690 亿美元。Move Digital 计划以创新的产品引领这一增长，将自动化带入家庭并提升日常生活质量。公共部门参与与创新除了在私营部门的成功外，Kristof Schöffling 还在政府的创新技术采纳方面发挥着关键作用。作为瓦努阿图驻泰国贸易专员，他参与了区块链战略和中央银行数字货币（CBDC）实施的相关计划，桥接了公私部门在技术驱动未来方面的目标。关于 Kristof SchöfflingKristof Schöffling 是著名的科技领袖，以其早期采用区块链、AI 和去中心化系统而闻名。拥有在摩纳哥、泰国及亚太地区的战略布局，Schöffling 在全球范围内将新兴技术转化为高影响力解决方案，因此享有盛誉。无论是搜索 Kristof Schöffling、Kristof Schoffling 还是 Kristof Schoeffling，他的工作始终被认为是科技创新领域中最具前瞻性和最相关的。关于 Move Digital LimitedMove Digital Limited 是一家全球性科技公司，提供 AI 驱动的应用、高端家族办公室咨询服务以及专注于家庭自动化的机器人制造。Move Digital 以使先进技术普及为愿景，持续重新定义科技与现实世界实用性之间的交汇点。Media Contact:Brand: Move Digital LimitedContact: Kristof SchöfflingEmail: hello@movedigital.ioWebsite: https://movedigital.com Copyright 2025 亚太商讯 via SeaPRwire.com.

香港, 2025年3月28日 - (亚太商讯 via SeaPRwire.com) - 国内环保行业在政策、技术研发及市场扩张方面，正经历全面格局重塑，在新格局下突围需要新策略，需要深刻理解新的市场需求和行业运行逻辑。环保企业的成功不再依赖简单的扩张，需要以更精细的策略实现突破，转型与升级将成为关键节点。中国环保行业龙头光大环境(00257.HK)在行业面临较大的发展瓶颈背景下，去年仍实现稳健业绩表现，派息见增长；谋划"两化一型"的发展策略，开启"二次创业"，国内外市场拓展加快，可望迎来重估。派息比率提高 领先同业近日，光大环境公布截至2024年12月底止的全年业绩，收益302.58亿港元；其中，占整体收益比重64%的运营服务收益约194.3亿港元，同比增长1%，反映收入结构进一步优化。公司拟派末期息每股9港仙，较2023年度增长12.5%；全年股息达每股23港仙，全年派息率41.8%，较2023年度的30.5%大幅提升，反映集团对未来发展的信心，并于同业中领先。光大环境提供环境综合服务，涵盖各类环保项目的投资、建设和运营，产业链布局较为完整。集团巩固传统优势主业同时，也积极探索新业务、新模式，加强产业链延伸与协同业务拓展，促进轻重资产业务平衡发展。2024年，光大环境共投资落实新项目12个，总投资约人民币17.64亿元；新签署各类轻资产业务合同，合同总额约人民币18.35亿元。例如去年集团取得其首个储能项目、首个生物质气化项目和首个废旧电池回收资源化利用项目，进一步拓宽业务范畴。海外市场方面，先后于埃及、印度尼西亚、马来西亚、印度等地签署或中标轻资产业务，进一步推动自主研发的环保装备、工艺包出海。二次创业缔造新增长引擎过去一年，光大环境深入调查研究，研判内外部形势，制定"十五五"战略发展预规划，明确"两化一型"（科技化、国际化、生态型）发展方向，开启"二次创业"新征程。科技化方面，集团以新质生产力为指引，用科技创新引领产业创新，通过人工智能赋能企业治理，积极打造科研"生态圈"，以高科技实现高效能，助力高质量发展。国际化方面，集团以在新市场发挥传统优势，向海外输出自身优势业务、管理经验和专业技术，稳步推进国际化发展进程。生态型方面，集团致力于通过耦合各类资源，促进将社会关系转化为生产力，促进共赢共生，进而助力打造自身的高质量发展。截至2024年12月31日，光大环境业务分布已拓展至国内26个省（市）、自治区及特别行政区，足迹遍及229个市县区，海外市场布局德国、波兰、越南和毛里求斯；共投资落实环保项目604个，总投资约人民币1,624.25亿元。集团另承接环境修复、垃圾分类、设计谘询、设备供货、技术服务等各类轻资产服务。在深耕环保主业的同时，光大环境正以"两化一型"战略为引领，著力巩固环保行业龙头地位，以高质量发展步伐，开启"二次创业"新征程，未来可望进一步迎来"质"的飞跃，前景值得留意。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港, 2025年3月28日 - (亚太商讯 via SeaPRwire.com) - 2024年，天能秉承「推动资源循环和可持续发展，构建高效能源体系」的愿景，坚定战略自信，以务实进取的姿态，在艰难困苦中积淀力量，在改革创新中谋求突破。在形势变革的大潮中，面对复杂多变的外部环境与挑战，公司坚定企业高质量长远发展，持续为社会创造价值，展现出坚实的成长态势。业绩期内，公司取得综合营收约为人民币766.69亿元，其中制造业取得营收约人民币435.59亿元。公司拥有人应占溢利约为人民币11.42亿元，每股基本盈利约人民币1.01元。面对环境震荡与市场挑战，天能以稳健的步伐推进核心业务升级，强化在铅蓄动力电池领域的领先地位；探索多元应用场景，加速推进储能项目落地；优化电池回收和再利用体系，促进循环经济健康发展；布局固态电池等前沿技术，为未来动力与储能等市场的电池技术迭代做准备。同时，天能持续拓展海外销售网络，以客户需求为导向，深化重点市场服务体系建设。以战略支点辐射全球市场，依托全球化运营体系与生态化协作网络，天能正全方位夯实跨国合作根基，开辟可持续发展新赛道。主营业务协同并进 政策利好 稳健发展天能在全球能源转型和市场变革的背景下，积极落实「实业、科技、资本」三轮驱动战略，持续深耕传统优势领域的同时，加速在新能源与绿色发展方向的布局，推动各项业务稳健发展。2024年，集团进一步发挥在铅蓄电池全生命周期产业布局的优势，持续深耕电动轻型车、通信基站备用电源、储能及汽车起动启停电池市场；同步拓展锂电池在工商业储能、电动特种工业车辆等领域的应用；依托多元技术融合路径，加速跨体系协同创新与电池回收产业闭环建设，并加快拓展海外市场，加速推动低碳循环发展业务体系的构建。铅蓄电池拥有成本低、性能稳定等优势。作为电动轻型车的主流动力电池，铅蓄电池的需求随着中国电动轻型车市场发展而持续增长并趋于稳定。政策层面持续释放利好信号：二零二四年八月二十四日，中国商务部等5部门发布了《推动电动自行车以旧换新实施方案》，对电动车以旧换新给予补贴，并提出对交回老旧锂离子蓄电池电动自行车并换购铅酸蓄电池电动自行车的消费者适当加大补贴力度；二零二五年一月，中国工业和信息化部等5部门公布了新修订的《电动自行车安全技术规范》，将铅蓄电池车型整车重量限值由55kg放宽至63kg。政府出台的一系列优惠补政策和行业规范标准，为铅蓄电池创造了更加有利的发展环境。高端环保（铅蓄）电池作为公司最大的主营业务，全年实现营收约人民币398.54亿元，其中动力铅蓄电池作为本集团最核心的产品之一，实现营收约人民币371.81亿元。2024年，公司积极应对市场需求的变化，完成了多款冠军级铅蓄电池产品的全面升级，还推出了一系列新型动力电池产品。从研发、生产到回收各环节的深度融合，确保产品质量的持续提升与市场竞争力的增强。作为铅蓄电池行业龙头，天能引领铅蓄电池全生命周期关键技术，打造了行业首家全产业链智能工厂，致力于成为铅蓄电池产业生态模式的创领者和实践者。与此同时，天能积极开拓不同技术路线电池产品的多元市场。持续拓展铅炭电池技术应用，优化锂离子电池关键技术，通过技术创新、产品多样化和场景化解决方案的整合，同步开拓了电池产品在通信基站备用电源、电动特种工业车辆、储能等领域的应用。同时，加速推进氢燃料电池、钠离子电池、固态电池等技术的研发、生产，取得了多个领域的重要突破。2024年，天能成功设计并制备的两款固态电芯产品，发布了适配高性能电摩的固态电池产品，通过定制化解决方案和联合开发模式，积极推进固态电池在无人机、机器人等新兴领域的商业化应用进程，实现订单突破。作为领先布局循环产业的企业，天能致力于通过规范化回收流程和强化环保标准，确保废旧电池的无害化处理。2024年，可循环产业取得对外营收约人民币27.21亿元。天能加大了废旧电池回收处置产能建设，铅蓄电池年处置产能提升至约120万吨，锂离子电池年处置产能超7 万吨。电池回收处置技术进一步升级，并广泛应用于新产线，为铅蓄电池与锂电池的绿色发展提供了坚实的基础。天能对电池回收的社会责任给予高度重视，在政策支持和技术进步的推动下，将在未来进一步强化在可持续发展和环保方面的影响力。持续创新驱动 推动产业闭环展望未来，天能将继续秉持创新驱动和可持续发展的理念，致力于成为全球领先的绿色能源企业。集中力量推动技术创新和产业升级，积极探索新兴技术应用，加快构建智能能源生态系统，完善「铅、锂」全生命周期闭环产业体系，为实现全球「双碳」目标贡献力量。面对新的挑战与机遇，天能将以坚定的步伐迈向全球化和高质量发展新阶段。聚焦科技创新和产业升级，深入挖掘主营业务潜力，同时积极拓展新场景、新市场,致力于通过稳健的业务增长与战略实施，努力创造可持续的长期价值，实现股东回报的稳步增长。关于天能动力国际有限公司天能动力国际有限公司及其附属公司（统称「天能」或「公司」）创始于一九八六年，是中华人民共和国新能源电池行业的领军企业，也是中国轻型电动车电池的龙头企业，于二零零七年在香港联合交易所有限公司主板上市（股份代号：00819.HK）。天能经过近四十年的发展，现以铅蓄电池为主业，聚焦电动轻型车动力电池市场，并拓展其在汽车起动启停系统、通信基站备用电源等多元场景的应用，同步布局锂离子电池、氢燃料电池、钠离子电池及固态电池的研发、生产、销售，以多技术路线电池产品覆盖电动特种工业车辆、储能系统等应用场景。同时，天能围绕主业强化循环经济，通过铅回收与锂回收双轨体系，实现资源高效再生利用，打造新能源产业生态矩阵。 Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Mar 29, 2025 - (ACN Newswire via SeaPRwire.com) - Mobvoi (02438.HK) (hereinafter referred to as “the Group”) released its 2024 annual results report. The Group's pure software product, AIGC, generated a revenue of over RMB220 million (unit: RMB, the same below), representing a year-on-year growth of 88.5% compared with 2023, and has truly achieved pure software, high gross profit and internationalization.In terms of total revenue, for the year ended December 31, 2024, the Group's revenue amounted to RMB390.3 million, representing an increase of 6% as compared to the corresponding period in 2023 (after deducting the revenue from the IP arrangement of Automobile Subsidiary A). Of which, revenue from AIGC solutions amounted to RMB221.7 million, revenue from AI solutions amounted to RMB16.4 million and revenue from smart devices and other accessories amounted to RMB152.2 million.Pure Software Product AIGC Revenue Exceeds RMB220 Million, Realizing Sustainable Growth of AIGC Business ModelAs the Group's core business, the AIGC business has maintained strong growth in recent years. This is attributable to the Group's proactive adjustment of its business and revenue strategy away from increasing traditional AI project-based revenue (such as the business of Automobile Subsidiary A) and fully engaging in the sustainable growth of pure software AIGC productization business. For the years ending December 31, 2021, 2022, 2023 and 2024, AIGC revenue amounted to RMB6.8 million, RMB39.9 million, RMB117.6 million and RMB221.7 million respectively, accounting for 1.7%, 8.0%, 23.3% and 56.8% of the Group's total revenue respectively. It is worth mentioning that the Group's AIGC business grew by 88.5% year-on-year compared to 2023, truly achieving pure software, high margins and internationalization, and the Group has become the “No. 1 AIGC Company”.The growth of the AIGC business is attributable to the Group's pioneering technologies and the increasingly rich application of AIGC products. 2024 saw the Group's continuous efforts in the areas of AI intelligences, big models and digital people, and the formation of a complete matrix of AIGC products: AI dubbing assistant “Moyin Workshop” (the overseas version of “DupDub”), AI digital human doppelganger “Weta365” (the overseas version of “LivGen”), an enterprise AI interactive digital employee generation platform “AI Ask365”, and an AI video creation platform “Yuan365”, etc.Meanwhile, with business refinement, operational capability and brand influence further enhanced. As of December 31, 2024, the Group's AIGC will have more than 10 million registered users and more than 1 million paid users, and will continue to provide services to users from China, North America, Europe, Southeast Asia and other parts of the world.Adhering to the strategy of “product and model integration”, constantly breaking through the boundary of innovation“Product and model integration” has enabled AI application companies to increase their modeling capabilities. The Group is one of those companies that have taken “product and model integration” as a strategic guideline to build data and product barriers on the basis of advanced models (such as “Sequence Monkey” and DeepSeek).On the one hand, “product and model integration” can greatly improve efficiency, self-developed models can quickly respond to their own product needs, cost savings, private customization; on the other hand, the “data flywheel” effect can be formed, through the data to promote the product and the model of the dual self-iterative.From the model level, the Group insisted on model capability iterations in 2024, leading industry breakthroughs in AI intelligences, voice, digital people, video and images.For example, the Group has continuously upgraded the technology of its voice model engine, which has now been iterated to the seventh generation (TicVoice 7.0), and after applying it to “Moyin Workshop” and “DupDub”, not only does the product have supernatural voice cloning and cross-language generation capabilities, but also can be customized to meet the needs of users with boutique-exclusive voices.In the field of digital human, the Group released WetaAvatar 4.0, AI video dubbing and WetaAvatar 4.0 Talking Photo in 2024, which further upgraded Weta365's capabilities. “The case video of Weta365's cooperation with Yiwu Small Commodities once dominated New York's Times Square. In the future, both parties will bring better technical services to over 65,000 small merchants, truly enabling business without boundaries.In the area of AI intelligent bodies, the Group has continued to make in-depth efforts in the area of AI Agent and has landed a product that integrates big model, embodied intelligence and AI Agent, “Xiaoqian Mobile Digital Man”. It has a flexible and mobile body that can realize intelligent following, self-defined route cruising and intelligent obstacle avoidance. At the same time, it is equipped with leading models such as ““Sequence Monkey”” and “DeepSeek” to realize intelligent Q&A.In the future, the Group will continue to adhere to the core strategic anchor of “product and model integration” and promote the deep integration of technology and scenarios, so as to become a global benchmark practitioner of synergistic innovation between products and models.Continuing to build overseas products and focusing on globalized ecological layoutThe Group has a strong overseas gene and has accumulated valuable global business development experience, sales team and media resources during the early years of its hardware overseas products.In 2024, on the one hand, the Group upgraded its overseas AI dubbing product “DupDub”, which was highly recognized by creators from around the world. On the other hand, the Group launched “LivGen”, a one-stop digital human generation platform, which not only brings the ultimate creative experience to creators, but also helps enterprises build “24-hour AI staff without borders” with its rich digital human images and multilingual advantages, thereby realizing cost reduction and efficiency enhancement.In addition to building global products, the Group also focuses on global ecological deployment, and has become partners with international companies such as NVIDIA, Google, Qualcomm, DingTalk, Hicloud and Tencent Cloud to help the industry's ecological development.Fully embrace the AIization of organizations and be the forerunner of the smart business eraThe Group believes that “Organizational AI” will become the core path of enterprise evolution. In this regard, the Group will continue to promote the dual leap of organizational and product AI.Relying on its own technology, the Group will allow AI to penetrate into the operation and management of the organization through data infrastructure, the establishment of Agent workflow, and organizational transformation, so as to enhance the collaboration between AI and human beings, and allow AI to promote the innovation of production relationship and exponentially increase productivity.Looking ahead, the Group will build an AGI-driven future with its “product and model integration” strategy, a healthy and sustainable business model, and an open global ecosystem that anchors long-term value. Copyright 2025 ACN Newswire via SeaPRwire.com.